
India’s VCs Are Beating Silicon Valley at Home
Key Takeaways
- •Indian VC firms now dominate top ten Indian tech investors
- •Accel is the sole US VC in the top‑10 list
- •US interest‑rate hikes curb American VC activity in India
- •Indian capital pledged $20.5 billion for U.S. investments in 2026
Pulse Analysis
The early 2010s saw Silicon Valley firms such as Sequoia and Accel racing to write multimillion‑dollar checks for fledgling Indian startups. Those bets paid off spectacularly—Tiger Global alone harvested roughly $3.5 billion from Flipkart’s 2018 sale to Walmart. Over the past decade, however, a homegrown venture ecosystem has emerged, built on founders‑turned‑investors, family offices and regionally focused funds that understand India’s fragmented consumer base, multilingual market and infrastructure quirks far better than distant partners.
Two forces have accelerated the home‑bias. First, Indian investors move faster, write smaller early‑stage checks and possess an instinct for product‑market fit in a country where purchasing power varies wildly. Second, macro‑economic headwinds in the United States—higher interest rates and a tougher fundraising climate—have forced many American VCs to tighten overseas exposure since 2022. The result is a stark reallocation: Accel is the sole US name among the top ten Indian tech backers, while domestic firms now dominate deal flow and board seats.
The confidence of Indian capital is now spilling beyond its borders. At the 2026 SelectUSA Investment Summit, Indian companies pledged a record $20.5 billion for U.S. projects ranging from AI infrastructure to advanced manufacturing, signaling an ambition to become global technology financiers. For American VCs, the message is clear: to stay relevant in India they must partner with local players or risk being outpaced. For Indian founders, the growing pool of domestic money offers faster, more nuanced support, reshaping the competitive landscape of global startup financing.
India’s VCs are beating Silicon Valley at home
Comments
Want to join the conversation?